Compare EUDA & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | TELA |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Singapore | United States |
| Employees | 123 | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.8M | 41.3M |
| IPO Year | N/A | 2019 |
| Metric | EUDA | TELA |
|---|---|---|
| Price | $15.80 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $55.00 | $2.00 |
| AVG Volume (30 Days) | 3.0K | ★ 84.9K |
| Earning Date | 12-19-2023 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | $134.73 | $10.23 |
| Revenue Next Year | $195.03 | $14.26 |
| P/E Ratio | $123.62 | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.33 | $0.50 |
| 52 Week High | $25.70 | $2.19 |
| Indicator | EUDA | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 44.21 |
| Support Level | $2.07 | $0.79 |
| Resistance Level | $18.90 | $0.94 |
| Average True Range (ATR) | 0.57 | 0.10 |
| MACD | -0.38 | -0.01 |
| Stochastic Oscillator | 21.22 | 13.11 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.